Welcome to our dedicated page for MYCO news (Ticker: MYCO), a resource for investors and traders seeking the latest updates and insights on MYCO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MYCO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MYCO's position in the market.
Mycotopia Therapies Inc. (OTC Pink: MYCO) has successfully completed its name and stock symbol change, reflecting its shift into the field of psychedelic therapies. This change aligns with the company's focus on technology-driven solutions for mental health issues such as anxiety, depression, PTSD, and more. Mycotopia is also working towards securing DTC eligibility for electronic share transactions in the U.S. The company aims to enhance mental wellness through integrated psychotherapy and advanced technology.
Mydecine Innovations Group is now officially listed on the NEO Exchange under the symbol NEO:MYCO after voluntarily delisting from the Canadian Securities Exchange. The company focuses on developing psychedelic-assisted therapeutics aimed at improving mental health. CEO Josh Bartch expressed optimism about increased liquidity and access to institutional investors enhancing transparency and visibility. This migration is part of a broader trend of companies moving to NEO, which supports fundraising for innovative sectors like psychedelics.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has appointed MNP LLP as its new auditor, replacing SHIM & Associates LLP. The company has filed a Notice of Change of Auditor on SEDAR. This change marks a shift in the company's financial oversight and aligns with its ongoing commitment to transparency and accountability in financial reporting. Stakeholders are encouraged to monitor future performance closely, as this transition may influence investor confidence and regulatory compliance.
Mydecine Innovations Group (CSE: MYCO, OTC: MYCOF) has successfully closed a bought-deal public offering, issuing 34.5 million units at C$0.50 each, raising C$17.25 million. This offering, led by Canaccord Genuity, includes an over-allotment option exercised in full. The company plans to utilize the proceeds for clinical trials, expanding its intellectual property portfolio, drug pipeline development, and general working capital. Each unit comprises one common share and a warrant, which will allow for further investment opportunities.
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) has filed its final short form prospectus in relation to its previously announced bought deal offering. The company plans to raise C$15 million by offering 30,000,000 units at C$0.50 each, with warrants exercisable at $0.70 over 36 months. An over-allotment option for an additional 4,500,000 units is also available. Proceeds will fund clinical trials, expand intellectual property, and support the development of its drug pipeline. The offering is expected to close by February 12, 2021, pending necessary approvals.
Mydecine Innovations Group (CSE:MYCO | OTC:MYCOF) has filed amended financial statements for the nine months ended September 30, 2020, reflecting significant adjustments. The revised reports show a decrease in total assets by $493,214, an increase in total liabilities by $1,830,594, and a drop in shareholders' equity by $2,323,808. Additionally, the net loss increased by $2,282,519 during this period. Key changes involve adjustments related to acquisitions and the write-off of inventory from subsidiaries, which amount to $458,921. All figures are in Canadian dollars.
Mydecine Innovations Group (CSE: MYCO, OTC: MYCOF) has announced a bought deal offering, filing a preliminary prospectus to raise C$15 million through the sale of 30 million units at C$0.50 each. Each unit consists of one common share and a warrant, exercisable for three years at $0.70. The offering includes an over-allotment option for an additional 4.5 million units. Funds will support clinical trials, expand the drug pipeline, and for general working capital. The offering is expected to close around February 3, 2021, pending necessary approvals.
Mydecine Innovations Group (CSE: MYCO) has appointed SHIM & Associates LLP as its new auditor, replacing MNP LLP. The change was necessitated as MNP lacked the capacity to review the Company’s interim financial statements for its bought deal offering due to a busy period. A Notice of Change of Auditor has been filed on SEDAR. The Canadian Securities Exchange has neither approved nor disapproved the contents of the news release.
Mydecine Innovations Group has requested the retraction of a press release titled “Mydecine Innovations Group Upsizes Previously Announced Bought Deal,” issued by Miller Thomson LLP.
This request is made due to the lack of prior authorization from Mydecine, indicating potential issues in communications and press management.
Miller Thomson LLP has requested the cancellation of their press release regarding a C$10 million bought deal offering by Mydecine Innovations Group. The request indicates that the press release was disseminated without the company's authorization, raising concerns about proper communication protocols.
